Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer.

Allibhai Z, Taremi M, Bezjak A, Brade A, Hope AJ, Sun A, Cho BC.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1064-70. doi: 10.1016/j.ijrobp.2013.08.020. Epub 2013 Oct 24.

PMID:
24210082
2.

Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer Tumors Greater Than 5 cm: Safety and Efficacy.

Woody NM, Stephans KL, Marwaha G, Djemil T, Videtic GM.

Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):325-31. doi: 10.1016/j.ijrobp.2015.01.045. Epub 2015 Apr 1.

PMID:
25841625
3.

Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients.

Taremi M, Hope A, Dahele M, Pearson S, Fung S, Purdie T, Brade A, Cho J, Sun A, Bissonnette JP, Bezjak A.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):967-73. doi: 10.1016/j.ijrobp.2010.12.039. Epub 2011 Mar 4.

PMID:
21377293
4.
5.

Impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.

Atallah S, Cho BC, Allibhai Z, Taremi M, Giuliani M, Le LW, Brade A, Sun A, Bezjak A, Hope AJ.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):532-8. doi: 10.1016/j.ijrobp.2014.03.003.

PMID:
24929163
6.

Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.

Kelley KD, Benninghoff DL, Stein JS, Li JZ, Byrnes RT, Potters L, Knisely JP, Zinkin HD.

Radiat Oncol. 2015 May 28;10:120. doi: 10.1186/s13014-015-0423-7.

7.

Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study.

Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA, Timmerman R.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82. doi: 10.1016/j.ijrobp.2008.11.042. Epub 2009 Feb 27.

PMID:
19251380
8.

Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.

Takeda A, Sanuki N, Kunieda E, Ohashi T, Oku Y, Takeda T, Shigematsu N, Kubo A.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):442-8. doi: 10.1016/j.ijrobp.2008.04.043. Epub 2008 Nov 5.

PMID:
18990507
9.

A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.

Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, Belderbos J.

J Thorac Oncol. 2012 Sep;7(9):1382-93. doi: 10.1097/JTO.0b013e318260e00d.

10.

Lung stereotactic body radiation therapy: regional nodal failure is not predicted by tumor size.

Marwaha G, Stephans KL, Woody NM, Reddy CA, Videtic GM.

J Thorac Oncol. 2014 Nov;9(11):1693-7. doi: 10.1097/JTO.0000000000000313.

11.

Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT).

Dunlap NE, Larner JM, Read PW, Kozower BD, Lau CL, Sheng K, Jones DR.

J Thorac Cardiovasc Surg. 2010 Sep;140(3):583-9. doi: 10.1016/j.jtcvs.2010.01.046. Epub 2010 May 15.

12.

Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.

Chang JY, Liu H, Balter P, Komaki R, Liao Z, Welsh J, Mehran RJ, Roth JA, Swisher SG.

Radiat Oncol. 2012 Sep 10;7:152.

13.

[An analysis of 20 consecutive patients treated with stereotactic body radiotherapy on Novalis Tx(®) for stage I non-small-cell lung cancer].

Guillerme F, Clavier JB, Schumacher C, Falcoz PE, Bourrhala K, Santelmo N, Hassler S, Schott R, Quoix E, Massard G, Noël G.

Cancer Radiother. 2013 Jul-Aug;17(4):272-81. doi: 10.1016/j.canrad.2013.01.021. Epub 2013 May 24. French.

PMID:
23712043
14.

Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.

Hayes JT, David EA, Qi L, Chen AM, Daly ME.

Clin Lung Cancer. 2015 Sep;16(5):379-84. doi: 10.1016/j.cllc.2015.01.006. Epub 2015 Jan 31.

15.

Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer.

Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, Swisher SG, Gillin M, Mohan R, Cox JD.

Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1350-7. doi: 10.1016/j.ijrobp.2010.04.049. Epub 2011 Jan 20.

16.

Stereotactic body radiation therapy for inoperable early stage lung cancer.

Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H.

JAMA. 2010 Mar 17;303(11):1070-6. doi: 10.1001/jama.2010.261.

17.

Comparison of outcomes following stereotactic body radiotherapy for non-small cell lung cancer in patients with and without pathological confirmation.

Haidar YM, Rahn DA 3rd, Nath S, Song W, Bazhenova L, Makani S, Fuster MM, Sandhu AP.

Ther Adv Respir Dis. 2014 Feb;8(1):3-12. doi: 10.1177/1753465813512545. Epub 2013 Dec 10.

PMID:
24334338
18.

Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".

Chang JY, Li QQ, Xu QY, Allen PK, Rebueno N, Gomez DR, Balter P, Komaki R, Mehran R, Swisher SG, Roth JA.

Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1120-8. doi: 10.1016/j.ijrobp.2014.01.022.

PMID:
24661665
19.

Excellent Cancer Outcomes Following Patient-adapted Robotic Lung SBRT But a Case for Caution in Idiopathic Pulmonary Fibrosis.

Bahig H, Filion E, Vu T, Roberge D, Lambert L, Bouchard M, Lavoie C, Doucet R, Nadeau DB, Chalaoui J, Campeau MP.

Technol Cancer Res Treat. 2015 Dec;14(6):667-76. doi: 10.7785/tcrt.2012.500445. Epub 2014 Nov 26.

PMID:
24988054
20.

Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study of 55 Patients.

Bhandari RP, Stanford JD, Packianathan S, Duggar WN, Kanakamedala MR, Zhang X, Giri SP, Kumar PP, Harrell LM, Mangana SH, Yang C, Vijayakumar S.

Oncology. 2016;91(4):194-204. Epub 2016 Jul 19.

PMID:
27427761

Supplemental Content

Support Center